导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.73% | 2008/4773 |
| 近一周 | -1.44% | 2175/5465 |
| 近一月 | -2.15% | 1492/5421 |
| 近一季 | -4.49% | 1832/5231 |
| 近半年 | -0.15% | 1415/4920 |
| 近一年 | 4.19% | 1907/4394 |
| 近两年 | 44.35% | 1706/2954 |
| 近三年 | 26.18% | 1256/2253 |
| 成立以来 | 79.61% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.44% 2788/4961 |
12.07% 2239/5312 |
- - |
- - |
| 2025 | 19.75% 2188/4813 |
0.48% 1836/3635 |
2.33% 1640/4076 |
17.04% 2565/4524 |
-0.49% 2512/4813 |
| 2024 | 11.40% 1326/3463 |
3.33% 594/2808 |
-1.86% 1118/3014 |
13.94% 2074/3129 |
-3.58% 2368/3463 |
| 2023 | -11.38% 1397/2656 |
1.30% 1599/2280 |
-4.19% 1087/2385 |
-2.26% 649/2515 |
-6.58% 1836/2655 |
| 2022 | -21.21% 1018/2207 |
-13.23% 720/1919 |
5.79% 822/2016 |
-13.87% 986/2113 |
-0.34% 1597/2208 |
| 2021 | -3.86% 933/1822 |
-0.56% 374/1255 |
4.79% 846/1330 |
-6.83% 994/1466 |
-0.97% 1291/1822 |
| 2020 | 32.53% 481/1250 |
-8.78% 631/1028 |
14.51% 548/1067 |
13.85% 307/1164 |
11.45% 539/1184 |
| 2019 | 39.96% 263/1092 |
26.02% 430/754 |
0.28% 182/804 |
2.77% 285/850 |
7.77% 400/918 |
| 2018 | -22.09% 229/834 |
- - |
- - |
- - |
-11.58% 319/691 |
| 2017 | 29.52% 64/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.42% 216/605 |
- - |
- - |
- - |
- - |
| 2015 | 13.23% 149/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 嘉实沪深300指数研究增强A VS. 长安沪深300非周期A(740101) |